Cargando…

Kefir consumption does not alter plasma lipid levels or cholesterol fractional synthesis rates relative to milk in hyperlipidemic men: a randomized controlled trial [ISRCTN10820810]

BACKGROUND: Fermented milk products have been shown to affect serum cholesterol concentrations in humans. Kefir, a fermented milk product, has been traditionally consumed for its potential health benefits but has to date not been studied for its hypocholesterolemic properties. METHODS: Thirteen heal...

Descripción completa

Detalles Bibliográficos
Autores principales: St-Onge, Marie-Pierre, Farnworth, Edward R, Savard, Tony, Chabot, Denise, Mafu, Akier, Jones, Peter JH
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2002
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC65674/
https://www.ncbi.nlm.nih.gov/pubmed/11825344
http://dx.doi.org/10.1186/1472-6882-2-1
_version_ 1782120169908207616
author St-Onge, Marie-Pierre
Farnworth, Edward R
Savard, Tony
Chabot, Denise
Mafu, Akier
Jones, Peter JH
author_facet St-Onge, Marie-Pierre
Farnworth, Edward R
Savard, Tony
Chabot, Denise
Mafu, Akier
Jones, Peter JH
author_sort St-Onge, Marie-Pierre
collection PubMed
description BACKGROUND: Fermented milk products have been shown to affect serum cholesterol concentrations in humans. Kefir, a fermented milk product, has been traditionally consumed for its potential health benefits but has to date not been studied for its hypocholesterolemic properties. METHODS: Thirteen healthy mildly hypercholesterolemic male subjects consumed a dairy supplement in randomized crossover trial for 2 periods of 4 wk each. Subjects were blinded to the dairy supplement consumed. Blood samples were collected at baseline and after 4 wk of supplementation for measurement of plasma total, low-density lipoprotein, and high-density lipoprotein cholesterol and triglyceride concentrations, as well as fatty acid profile and cholesterol synthesis rate. Fecal samples were collected at baseline and after 2 and 4 wk of supplementation for determination of fecal short chain fatty acid level and bacterial content. RESULTS: Kefir had no effect on total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglyceride concentrations nor on cholesterol fractional synthesis rates after 4 wk of supplementation. No significant change on plasma fatty acid levels was observed with diet. However, both kefir and milk increased (p < 0.05) fecal isobutyric, isovaleric and propionic acids as well as the total amount of fecal short chain fatty acids. Kefir supplementation resulted in increased fecal bacterial content in the majority of the subjects. CONCLUSIONS: Since kefir consumption did not result in lowered plasma lipid concentrations, the results of this study do not support consumption of kefir as a cholesterol-lowering agent.
format Text
id pubmed-65674
institution National Center for Biotechnology Information
language English
publishDate 2002
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-656742002-02-25 Kefir consumption does not alter plasma lipid levels or cholesterol fractional synthesis rates relative to milk in hyperlipidemic men: a randomized controlled trial [ISRCTN10820810] St-Onge, Marie-Pierre Farnworth, Edward R Savard, Tony Chabot, Denise Mafu, Akier Jones, Peter JH BMC Complement Altern Med Research Article BACKGROUND: Fermented milk products have been shown to affect serum cholesterol concentrations in humans. Kefir, a fermented milk product, has been traditionally consumed for its potential health benefits but has to date not been studied for its hypocholesterolemic properties. METHODS: Thirteen healthy mildly hypercholesterolemic male subjects consumed a dairy supplement in randomized crossover trial for 2 periods of 4 wk each. Subjects were blinded to the dairy supplement consumed. Blood samples were collected at baseline and after 4 wk of supplementation for measurement of plasma total, low-density lipoprotein, and high-density lipoprotein cholesterol and triglyceride concentrations, as well as fatty acid profile and cholesterol synthesis rate. Fecal samples were collected at baseline and after 2 and 4 wk of supplementation for determination of fecal short chain fatty acid level and bacterial content. RESULTS: Kefir had no effect on total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglyceride concentrations nor on cholesterol fractional synthesis rates after 4 wk of supplementation. No significant change on plasma fatty acid levels was observed with diet. However, both kefir and milk increased (p < 0.05) fecal isobutyric, isovaleric and propionic acids as well as the total amount of fecal short chain fatty acids. Kefir supplementation resulted in increased fecal bacterial content in the majority of the subjects. CONCLUSIONS: Since kefir consumption did not result in lowered plasma lipid concentrations, the results of this study do not support consumption of kefir as a cholesterol-lowering agent. BioMed Central 2002-01-22 /pmc/articles/PMC65674/ /pubmed/11825344 http://dx.doi.org/10.1186/1472-6882-2-1 Text en Copyright © 2002 St-Onge et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.
spellingShingle Research Article
St-Onge, Marie-Pierre
Farnworth, Edward R
Savard, Tony
Chabot, Denise
Mafu, Akier
Jones, Peter JH
Kefir consumption does not alter plasma lipid levels or cholesterol fractional synthesis rates relative to milk in hyperlipidemic men: a randomized controlled trial [ISRCTN10820810]
title Kefir consumption does not alter plasma lipid levels or cholesterol fractional synthesis rates relative to milk in hyperlipidemic men: a randomized controlled trial [ISRCTN10820810]
title_full Kefir consumption does not alter plasma lipid levels or cholesterol fractional synthesis rates relative to milk in hyperlipidemic men: a randomized controlled trial [ISRCTN10820810]
title_fullStr Kefir consumption does not alter plasma lipid levels or cholesterol fractional synthesis rates relative to milk in hyperlipidemic men: a randomized controlled trial [ISRCTN10820810]
title_full_unstemmed Kefir consumption does not alter plasma lipid levels or cholesterol fractional synthesis rates relative to milk in hyperlipidemic men: a randomized controlled trial [ISRCTN10820810]
title_short Kefir consumption does not alter plasma lipid levels or cholesterol fractional synthesis rates relative to milk in hyperlipidemic men: a randomized controlled trial [ISRCTN10820810]
title_sort kefir consumption does not alter plasma lipid levels or cholesterol fractional synthesis rates relative to milk in hyperlipidemic men: a randomized controlled trial [isrctn10820810]
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC65674/
https://www.ncbi.nlm.nih.gov/pubmed/11825344
http://dx.doi.org/10.1186/1472-6882-2-1
work_keys_str_mv AT stongemariepierre kefirconsumptiondoesnotalterplasmalipidlevelsorcholesterolfractionalsynthesisratesrelativetomilkinhyperlipidemicmenarandomizedcontrolledtrialisrctn10820810
AT farnworthedwardr kefirconsumptiondoesnotalterplasmalipidlevelsorcholesterolfractionalsynthesisratesrelativetomilkinhyperlipidemicmenarandomizedcontrolledtrialisrctn10820810
AT savardtony kefirconsumptiondoesnotalterplasmalipidlevelsorcholesterolfractionalsynthesisratesrelativetomilkinhyperlipidemicmenarandomizedcontrolledtrialisrctn10820810
AT chabotdenise kefirconsumptiondoesnotalterplasmalipidlevelsorcholesterolfractionalsynthesisratesrelativetomilkinhyperlipidemicmenarandomizedcontrolledtrialisrctn10820810
AT mafuakier kefirconsumptiondoesnotalterplasmalipidlevelsorcholesterolfractionalsynthesisratesrelativetomilkinhyperlipidemicmenarandomizedcontrolledtrialisrctn10820810
AT jonespeterjh kefirconsumptiondoesnotalterplasmalipidlevelsorcholesterolfractionalsynthesisratesrelativetomilkinhyperlipidemicmenarandomizedcontrolledtrialisrctn10820810